经过四年的低迷期,生物科技行业正在迎来复苏,多个因素推动其股价回升。从积极的药物试验结果到活动的增加,再到药品推出的成功和利率下降,生物科技股的前景正在改善。分析师认为,投资者仍有机会把握这个反弹的机会,特别是一些潜力股值得关注。生物科技股票正在走出四年的低迷期。以该行业为代表的SPDR S&P生物科技交易所交易基金(XBI),截至10月31日,今年上涨了25%,超越了标准普尔500指数(SPX)...
Source Link经过四年的低迷期,生物科技行业正在迎来复苏,多个因素推动其股价回升。从积极的药物试验结果到活动的增加,再到药品推出的成功和利率下降,生物科技股的前景正在改善。分析师认为,投资者仍有机会把握这个反弹的机会,特别是一些潜力股值得关注。生物科技股票正在走出四年的低迷期。以该行业为代表的SPDR S&P生物科技交易所交易基金(XBI),截至10月31日,今年上涨了25%,超越了标准普尔500指数(SPX)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.